N-[(E)-3-[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]-2,3-dihydroxy-5-nitrobenzamide

This compound is a synthetic small molecule nucleoside analog with the molecular formula C19H19N7O8 and a molecular weight of approximately 473.40 g/mol[1][5]. It is classified as an experimental drug and has not been approved for any clinical use or indication[2][3]. Structurally related to adenosine derivatives due to its purine base and ribose-like sugar moiety linked to a substituted benzamide group with nitro and dihydroxy functionalities. The compound has been studied in structural biology as a ligand for catechol O-methyltransferase (COMT), suggesting it may act as an inhibitor of this enzyme[7]. COMT is involved in the degradation of catecholamine neurotransmitters such as dopamine. No clinical trials or therapeutic indications are reported for this molecule.

Other names

N-{(2E)-3-[(2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxytetrahydro-2-furanyl]-2-propen-1-yl}-2,3-dihydroxy-5-nitrobenzamideN-{(E)-3-[ (2R,3S,4R,5R ) - 5 - (6-Amino-purin -9-Yl ) - 3 , 4-Dihydroxytetrahydrofuran - 2-Yl ] prop - 2-Enyl } - 2 , 3-Dihydroxy - 5-Nitrobenzene -1-CarboxamideN-{(E)-3-[ (2R , ) ... ]}CL4CL-4CL 4